FrancophonIA/ELRC3.0 huggingface dataset:
English: Zubsolv is a medicine used in adults and adolescents aged over 15 years to treat dependence on opioid (narcotic) drugs such as heroin or morphine.
Estonian: Zubsolv on ravim, mida kasutatakse opioididest (narkootilised ained), nt heroiinist või morfiinist, tekkinud sõltuvuse raviks täiskasvanutel ja üle 15-aastastel noorukitel.
English: It is not intended to provide practical advice on how to use Zubsolv.
Estonian: Hindamisaruandes ei anta Zubsolvi kasutamise praktilisi nõuandeid.
English: How does Zubsolv work?
Estonian: Kuidas Zubsolv toimib?
English: For the full list of side effects reported with Zubsolv, see the package leaflet.
Estonian: Zubsolvi kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: How is Zubsolv used?
Estonian: Kuidas Zubsolvi kasutatakse?
English: For practical information about using Zubsolv, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Zubsolvi kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: For more information about treatment with Zubsolv, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Zubsolviga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: However, buprenorphine tablets have been misused by drug addicts who dissolve the tablets and inject themselves with the resulting solution.
Estonian: Sõltlased on buprenorfiini tablette siiski väärkasutanud neid lahustades ja saadud lahust süstides.
English: What benefits of Zubsolv have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Zubsolvi kasulikkus?
English: This is because, when injected, naloxone counteracts the effects of opioids, causing the patient to experience acute withdrawal symptoms.
Estonian: Naloksooni lisamine aitab ennetada ravimi väärkasutamist, kuna süstimisel neutraliseerib see opioidi toime, põhjustades patsiendile ägedaid võõrutussümptomeid.
English: Annex A_en
Estonian: Annex A_et
English: 90 capsules blister (PVC/Aclar/alu)
Estonian: Blisterpakend (PVC/Aclar/alumiinium)
English: 17 February 2011 EMA/121971/2011 EMEA/H/C/002091
Estonian: 17. veebruar 2011 EMA/121971/2011 EMEA/H/C/002091
English: • metastatic cancer of the ovary (when the cancer has spread to other parts of the body) after at least one other treatment has failed;
Estonian: • metastaasidega munasarjavähk (kui vähk on levinud teistesse kehaosadesse), kui vähemalt üks muu ravi on ebaõnnestunud;
English: The letter from the company notifying the Agency of the withdrawal of the application is available under the tab ‘All documents'.
Estonian: Ettevõtte kiri, milles ta teatab Euroopa Ravimiametile oma taotluse tagasivõtmisest, on avaldatud jaotises „All documents”.
English: This prevents the cancer cells from dividing and they eventually die.
Estonian: Selle tulemusel ei saa vähirakud jaguneda ning lõpuks hävivad.
English: As the CHMP was evaluating the initial documentation provided by the company, it had not yet made any recommendations.
Estonian: Et inimravimite komitee alles hindas ettevõtte esitatud esialgseid dokumente, ei olnud ta veel soovitusi andnud.
English: When the enzyme is blocked, the DNA strands break.
Estonian: Kui see ensüüm on blokeeritud, siis DNA ahelad lagunevad.
English: It was also to be used together with cisplatin (another anticancer medicine) to treat women with cervical cancer (cancer of the cervix), when the cancer had come back after radiotherapy, or when the disease was at an advanced stage (stage IVB: the cancer has spread beyond the cervix).
Estonian: Ravimit kavatseti kasutada ka koos tsisplatiiniga (samuti vähiravim) emakakaelavähi raviks juhtudel, mil vähk on pärast kiiritusravi naasnud või on kaugelearenenud staadiumis (IVB staadium: vähk on levinud emakakaelast kaugemale).
English: Withdrawal of the marketing authorisation application for Topotecan SUN (topotecan) EMA/121971/2011
Estonian: Müügiloa taotluse tagasivõtmise teave: Topotecan SUN (topotekaan) EMA/121971/2011
English: What is Topotecan SUN?
Estonian: Mis on Topotecan SUN?
English: The company provided data from the published literature on topotecan.
Estonian: Ettevõte esitas topotekaani kohta teaduslikus kirjanduses avaldatud andmed.
English: It contains the active substance topotecan.
Estonian: See sisaldab toimeainena topotekaani.
English: No additional studies were needed as Topotecan SUN is a generic medicine that is given by infusion and contains the same active substance as the reference medicine, Hycamtin.
Estonian: Lisauuringuid ei olnud vaja, sest Topotecan SUN on infusioonina manustatav geneeriline ravim, mis sisaldab sama toimeainet kui võrdlusravim Hycamtin.
English: Withdrawal of the marketing authorisation application for Topotecan SUN (topotecan)
Estonian: Müügiloa taotluse tagasivõtmise teave: Topotecan SUN (topotekaan)
English: This means that Topotecan SUN was intended to be similar to a ‘reference medicine' already authorised in the European Union called Hycamtin.
Estonian: See tähendab, et Topotecan SUN pidi olema sarnane võrdlusravimiga Hycamtin, millel juba on Euroopa Liidus müügiluba.
English: This means that the CHMP was still evaluating the initial documentation provided by the company.
Estonian: Seega inimravimite komitee alles hindas ettevõtte esitatud esialgseid dokumente.
English: It blocks an enzyme called topoisomerase I, which is involved in the division of DNA.
Estonian: See blokeerib ensüümi topoisomeraas-I, mis osaleb DNA jagunemises.
English: • small cell lung cancer, when the cancer has relapsed (come back).
Estonian: • relapseerunud (taastunud) väikerakk-kopsuvähk.
English: Topotecan SUN also affects non-cancer cells, which causes side effects.
Estonian: Topotecan SUN mõjutab ka muid rakke peale vähirakkude ja see põhjustab kõrvalnähte.
English: Topotecan SUN was to be used on its own to treat patients with:
Estonian: Topotecan SUNi kavatseti kasutada ainsa ravimina patsientidel, kellel on:
English: On 3 January 2011, Sun Pharmaceutical Industries Europe B.V. officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Topotecan SUN for the treatment metastatic cancer of the ovary, small cell lung cancer and cervical cancer.
Estonian: ametlikult inimravimite komiteele, et soovib võtta tagasi metastaasidega munasarjavähi, väikerakk-kopsuvähi ja emakakaelavähi raviks ette nähtud ravimi Topotecan SUN müügiloa taotluse.
English: Topotecan SUN was developed as a ‘generic medicine'.
Estonian: Topotecan SUN töötati välja geneerilise ravimina.
English: The active substance in Topotecan SUN, topotecan, is an anticancer medicine that belongs to the group ‘topoisomerase inhibitors'.
Estonian: Topotecan SUNi toimeaine topotekaan on topoisomeraasi inhibiitorite rühma kuuluv vähiravim.
English: What did the company present to support its application?
Estonian: Mis dokumendid esitas ettevõte inimravimite komiteele oma taotluse toetuseks?
English: Topotecan SUN is a powder to be made up into a solution for infusion (drip into a vein).
Estonian: Topotecan SUN on pulber, millest valmistatakse infusioonilahus (veeni tilgutatav lahus).
English: How is Topotecan SUN expected to work?
Estonian: Milline on Topotecan SUNi eeldatav toime?
English: What was Topotecan SUN expected to be used for?
Estonian: Milleks kavatseti Topotecan SUNi kasutada?
English: Milk can be taken immediately.
Estonian: Piima võib lüpsta kohe.
English: There are no specific risks for the user.
Estonian: Kasutajale eririskid puuduvad.
English: This summary was last updated on 27 January 2011.
Estonian: Kokkuvõtte viimane uuendus: 27/01/2011.
English: This will help to protect against the disease.
Estonian: See aitab loomi haiguse eest kaitsta.
English: Afterward a single ‘booster' can be given every six months to maintain the vaccine's effect.
Estonian: Hiljem võib teha iga kuue kuu järel ühe kordussüsti, et säilitada vaktsiini mõju.
English: This increase can sometimes be higher (up to 1.6º C in adult cows and up to 2.2º C in calves).
Estonian: Vahel võib temperatuuritõus olla ka suurem (täiskasvanud lehmadel kuni 1,6 ºC ja vasikatel kuni 2,2 ºC).
English: This slight swelling lasts for less than a day in most cases.
Estonian: Enamasti kestab kerge paistetus vähem kui ühe ööpäeva.
English: The rise in temperature is temporary and spontaneously resolved within two days without treatment.
Estonian: Kehatemperatuuri tõus on ajutine ja kaob kahe päeva jooksul ilma ravita iseenesest.
English: Studies also looked at the safety of the vaccine in pregnant animals.
Estonian: Uuringutes uuriti ka vaktsiini ohutust tiinetel loomadel.
English: The virus is alive, but it has also been attenuated (weakened) to further lower its ability to cause infection.
Estonian: Viirus on elus, kuid nõrgestatud, et veelgi vähendada viiruse võimet tekitada nakkus.
English: What is the time to allow before milk can be taken from the animal for human consumption?
Estonian: Kui pikk on aeg, mille kestel ei või loomalt lüpsta inimesele tarbimiseks piima?
English: Vaccines work by ‘teaching' the immune system (the body's natural defences) how to defend itself against a disease.
Estonian: Vaktsiinid n-ö õpetavad immuunsüsteemi (organismi loomulikke kaitsemehhanisme) ennast haiguse eest kaitsma.
English: The efficacy of the vaccine was studied in three laboratory studies including one study looking at the duration of immunity.
Estonian: Vaktsiini efektiivsust uuriti kolmes laboriuuringus, neist ühes vaadeldi immuunsuse kestust.
English: The studies also showed that the vaccine can be used in pregnant cattle as well in the presence of maternally derived antibodies.
Estonian: Samuti näitasid uuringud, et vaktsiini võib kasutada tiinetel veistel ja ka emasloomalt saadud antikehade olemasolu korral.
English: This vaccine is a marker vaccine and can enable a differential testing of vaccinated and naturally infected cattle, which is a useful tool in eradication campaigns.
Estonian: Vaktsiin on markervaktsiin ja võimaldab vaktsineeritud ja looduslikult nakatunud veiste eristavat uurimist, millest võib olla kasu haigustõrje kampaania ajal.
English: What is the time to allow before the animal can be slaughtered and the meat used for human consumption (withdrawal period)?
Estonian: Kui pikk on aeg, mille kestel ei või looma tappa ega tema liha tarvitada toiduks (keeluaeg)?
English: The first injection can be given to calves from three months of age.
Estonian: Esimese süsti võib teha vähemalt 3-kuustele vasikatele.
English: The injections should be preferably administered on the alternate sides of the neck.
Estonian: Süstid tuleb eelistatult teha kaela vastaskülgedele.
English: Hiprabovis IBR Marker Live is a vaccine that contains an IBR virus that has been genetically modified to delete two genes so that the virus is less ‘pathogenic' (less able to cause a disease).
Estonian: Hiprabovis IBR Marker Live on vaktsiin, mis sisaldab geneetiliselt muundatud IBR-viirust: sellest on eemaldatud kaks geeni, et viirus oleks vähem patogeenne (haigust vähem tekitav).
English: Animals can also show a temporary inflammation at the site of injection in the 72 hours after-vaccination.
Estonian: Loomadel võib ilmneda ka 72 tunni jooksul pärast vaktsineerimist süstekoha ajutine põletikuline reaktsioon.
English: The European Commission granted a marketing authorisation valid throughout the European Union, for Hiprabovis IBR Marker Live to Laboratorios Hipra S.A. on 27 January 2011.
Estonian: Euroopa Komisjon andis vaktsiini Hiprabovis IBR Marker Live müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele Laboratorios Hipra S.A. 27/01/2011.
English: In the future, if the animals are exposed to the IBR virus, the immune system will be able to respond more quickly.
Estonian: Kui loomad puutuvad hiljem kokku IBR-viirusega uuesti, tekivad antikehad kiiremini.
English: The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Hiprabovis IBR Marker Live exceed the risks for the active immunisation of cattle from three months of age against Bovine Herpes Virus type 1 to reduce the clinical signs of infectious bovine IBR and field virus excretion and recommended that Hiprabovis IBR Marker Live be given a marketing authorisation.
Estonian: Veterinaarravimite komitee otsustas, et vaktsiini Hiprabovis IBR Marker Live kasulikkus vähemalt kolme kuu vanuste veiste aktiivseks immuniseerimiseks veiste 1. tüüpi herpesviiruse vastu, et leevendada veiste nakkusliku rinotrahheiidi kliinilisi nähtusid ja vähendada viiruse levikut, on suurem kui vaktsiiniga kaasnevad riskid, ning soovitas anda vaktsiini Hiprabovis IBR Marker Live müügiloa.
English: After vaccination, animals may show a slight increase in body temperature up to 1° C, in the four days following vaccination.
Estonian: Nelja päeva jooksul pärast vaktsineerimist võib loomadel ajutiselt tõusta kehatemperatuur, tavaliselt kuni 1° võrra.
English: The vaccine is given to animals as two injections, three weeks apart, into the neck muscles.
Estonian: Vaktsiini manustatakse loomadele kahe süstina kaelalihasesse.
English: The safety of Hiprabovis IBR Marker Live was investigated in a number of laboratory studies and in one field trial that included dairy cows and fattening cattle.
Estonian: Vaktsiini Hiprabovis IBR Marker Live ohutust uuriti mitmes laboriuuringus ja ühes piimalehmadel ja nuumveistel tehtud väliuuringus.
English: It is a powder for suspension for injection that contains a modified live infectious bovine rhinotracheitis (IBR) virus (also known as Bovine Herpes Virus type 1).
Estonian: See on süstesuspensiooni pulber, mis sisaldab veiste nakkusliku rinotrahheiidi viiruse (IBR-viirus ehk veiste 1. tüüpi herpesviirus) modifitseeritud elusvormi.
English: A field study also looked at the efficacy of Hiprabovis IBR Marker Live, compared with a dummy vaccine, on reducing the clinical signs of the disease and virus excretion.
Estonian: Väliuuringus vaadeldi ka vaktsiini Hiprabovis IBR Marker Live ja toimeta vaktsiini efektiivsust haiguse kliiniliste nähtude ja viiruse leviku vähendamisel.
English: Hiprabovis IBR Marker Live is used to vaccinate cattle (cows and calves) against the respiratory infections caused by IBR.
Estonian: Vaktsiini Hiprabovis IBR Marker Live kasutatakse veiste (lehmade ja vasikate) vaktsineerimiseks veiste nakkusliku rinotrahheiidi (IBR) vastu.
English: The studies showed that the vaccine is safe for cattle from three months of age and that it reduces the clinical signs of IBR and field virus excretion.
Estonian: Uuringud näitasid, et vaktsiin on vähemalt 3 kuu vanustele veistele ohutu ning leevendab veiste nakkusliku rinotrahheiidi nähtusid ja vähendab viiruse levikut.
English: Hiprabovis IBR Marker Live is a vaccine.
Estonian: Hiprabovis IBR Marker Live on vaktsiin.
English: The vaccine is used to reduce the clinical signs of IBR and the excretion (shedding) of the virus by the infected animals.
Estonian: Vaktsiini kasutatakse veiste nakkusliku rinotrahheiidi kliiniliste tunnuste leevendamiseks ja nakatunud loomadelt viiruse eritumise (ülekandumise) vähendamiseks.
English: Live vaccine against infectious bovine rhinotracheitis (IBR)
Estonian: Veiste nakkusliku rinotrahheiidi (IBR) elusvaktsiin
English: What is Hiprabovis IBR Marker Live?
Estonian: Mis on Hiprabovis IBR Marker Live?
English: Why has Hiprabovis IBR Marker Live been approved?
Estonian: Miks vaktsiin Hiprabovis IBR Marker Live heaks kiideti?
English: What is the risk associated with Hiprabovis IBR Marker Live?
Estonian: Mis riskid vaktsiiniga Hiprabovis IBR Marker Live kaasnevad?
English: When Hiprabovis IBR Marker Live is given to cattle, the animals' immune systems recognise the viruses as ‘foreign' and make defences against it.
Estonian: Hiprabovis IBR Marker Live, peab immuunsüsteem viirust võõraks ja tekitab selle vastu antikehi.
English: How has Hiprabovis IBR Marker Live been studied?
Estonian: Kuidas vaktsiini Hiprabovis IBR Marker Live uuriti?
English: How does Hiprabovis IBR Marker Live work?
Estonian: Kuidas Hiprabovis IBR Marker Live toimib?
English: Other information about Hiprabovis IBR Marker Live:
Estonian: Muu teave vaktsiini Hiprabovis IBR Marker Live kohta
English: What benefit has Hiprabovis IBR Marker Live shown during the studies?
Estonian: Milles seisneb uuringute põhjal vaktsiini Hiprabovis IBR Marker Live kasulikkus?
English: The European Commission issued a decision on 14 July 2009.
Estonian: Euroopa Komisjon tegi otsuse 14. juulil 2009.
English: Prof Pirożynski (Poland)
Estonian: Prof. Pirożynski (Poola)
English: 23 April 2009
Estonian: 23. aprill 2009
English: The company wanted the authorisation to be recognised in Latvia, Lithuania, Poland, Slovakia and Slovenia (the ‘concerned Member States').
Estonian: Ettevõte soovis müügiloa tunnustamist Leedus, Lätis, Poolas, Slovakkias ja Sloveenias (asjaomased liikmesriigid).
English: Ref. EMEA/CHMP/499991/2009 EMEA/H/A-29/1061
Estonian: London, 16. juuli 2009 Viide EMEA/495504/2009 EMEA/H/A-29/1061
English: The marketing authorisation in the Czech Republic should also be suspended.
Estonian: Ka Tšehhi Vabariigis antud müügiluba tuleb peatada.
English: It can also be used in systemic infections (infections that affect the whole body), including tropical infections.
Estonian: Seda võib kasutada ka süsteemsete infektsioonide (kogu organismi mõjutavad infektsioonid), sealhulgas troopiliste infektsioonide korral.
English: 25 September 2008
Estonian: 15. detsember 2008
English: What is Prokanazol?
Estonian: Mis on Prokanazol?
English: Based on evaluation of the currently available data and the scientific discussion within the Committee, the CHMP was of the opinion that bioequivalence to the reference medicinal product has not been shown.
Estonian: Tuginedes olemasolevatele andmetele ja komiteesisesele teaduslikule arutelule, leidis inimravimite komitee, et bioekvivalentsus võrdlusravimiga ei ole tõendatud.
English: Prokanazol is also marketed under the name Prokanaz.
Estonian: Prokanazoli turustatakse ka Prokanazi nime all.
English: It can be used in local infections, such as infections of the vulva or vagina (female sexual organs) or infections of the skin or the eye.
Estonian: Seda võib kasutada lokaalsete infektsioonide korral, näiteks häbeme- või tupe- (naise suguorganid) infektsioon või naha- või silmainfektsioon.
English: The company PRO.MED.CS Praha a. s. submitted Prokanazol for mutual recognition on the basis of the initial authorisation granted by the Czech Republic on 30 July 2003.
Estonian: Ettevõte PRO.MED.CS Praha a. s. esitas avalduse Prokanazoli müügiloa vastastikuse tunnustamise menetluseks Tšehhi Vabariigis 30. juulil 2003 antud esialgse müügiloa põhjal.
English: Prokanazol can be used against a range of fungi and yeasts, including Candida, Aspergillus and Cryptococcus.
Estonian: Prokanazoli kasutatakse mitmesuguste seennakkuste ja pärmiseente, sealhulgas Candida, Aspergillus'e ja Cryptococcus'e põhjustatud seennakkuste raviks.
English: Co-rapporteur:
Estonian: Kaasettekandja(d):
English: Prokanazol is a generic medicine that is based on a reference medicine authorised in the Czech Republic (Sporanox 100 mg capsules).
Estonian: Prokanazol on geneeriline ravim, mis tugineb Tšehhi Vabariigis kinnitatud müügiloaga võrdlusravimile (Sporanox 100 mg kapslid).
English: However, because the concerned Member States were not able to reach an agreement, the Czech medicines regulatory agency referred the matter to the CHMP for arbitration on 31 July 2008.
Estonian: Et liikmesriigid ei jõudnud üksmeelele, tegi Tšehhi pädev asutus 31. juulil 2008 Euroopa Ravimiametile esildise vahekohtumenetluse alustamiseks.
English: In addition, the Committee has also recommended that the marketing authorisation for Prokanazol in the Czech Republic should be suspended.
Estonian: Lisaks soovitas komitee peatada Prokanazoli müügiluba ka Tšehhi Vabariigis.
English: The CHMP therefore concluded that the benefits of Prokanazol do not outweigh its risks and recommended that the marketing authorisation should not be granted in the concerned Member States.
Estonian: Seetõttu järeldas inimravimite komitee, et Prokanazoli kasulikkus ei ole suurem kui sellega kaasnevad riskid ning soovitas asjaomastes liikmesriikides müügiluba mitte anda.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded that the benefits of Prokanazol do not outweigh its risks, and that the marketing authorisation granted in the Czech Republic cannot be recognised in other Member States of the EU.
Estonian: Euroopa Ravimiameti inimravimite komitee otsustas, et Prokanazoli kasulikkus ei ole suurem kui sellega kaasnevad riskid ja Tšehhi Vabariigis antud müügiluba ei või tunnustada Euroopa Liidu teistes liikmesriikides.
English: Why was Prokanazol reviewed?
Estonian: Miks Prokanazoli müügiluba uuesti läbi vaadati?
English: The European Medicines Agency has completed an arbitration procedure following a disagreement among Member States of the European Union (EU) regarding the authorisation of the medicine Prokanazol.
Estonian: Euroopa Ravimiamet (EMEA) on lõpetanud vahekohtumenetluse, mis algatati pärast seda, kui Euroopa Liidu liikmesriigid ei jõudnud kokkuleppele ravimi Prokanazol heakskiitmises.
English: The grounds for the referral were that one of the concerned Member States, Poland, did not agree that enough evidence had been presented to show that Prokanazol was ‘bioequivalent' to the reference medicine.
Estonian: Esildise tegemine oli tingitud asjaolust, et ühe asjaomase liikmesriigi - Poola - arvates ei olnud Prokanazoli bioekvivalentsus võrdlusravimiga piisavalt tõendatud.
English: It is used to treat adults with infections caused by fungi.
Estonian: Seda kasutatakse seeninfektsiooniga täiskasvanute raviks.
English: Prokanazol is an antifungal medicine.
Estonian: Prokanazol on seenevastane ravim.
English: The active substance in Prokanazol, itraconazole, is an antifungal substance that belongs to the group ‘triazoles'.
Estonian: Prokanazoli toimeaine itrakonasool on triasoolide rühma kuuluv seenevastane ravim.
English: Questions and answers on the referral for Prokanazol capsules containing itraconazole 100 mg
Estonian: Teave Prokanazoli kapslite (sisaldavad 100 mg itrakonasooli) esildismenetluse kohta
English: Company responses provided on: 15 December 2008 Opinion date:
Estonian: Dr. van Zwieten-Boot (Madalmaad) Esildismenetluse alguse kuupäev: 25. september 2008 Ettevõtte vastuste kuupäev:
English: Fiasp received a marketing authorisation valid throughout the EU on 9 January 2017.
Estonian: Fiasp on saanud müügiloa, mis kehtib kogu ELis, 9. jaanuaril 2017.
English: Further information on Fiasp can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/fiasp.
Estonian: Lisateave Fiaspi kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/fiasp.
English: However, it is unclear whether this changes the risk of diabetic complications.
Estonian: Ei ole siiski selge, kas see mõjutab diabeeditüsistuste riski.
English: What measures are being taken to ensure the safe and effective use of Fiasp?
Estonian: Mis meetmed võetakse, et tagada Fiaspi ohutu ja efektiivne kasutamine?
English: Other information about Fiasp
Estonian: Muu teave Fiaspi kohta
English: Diabetes is a disease in which blood glucose is high, either because the body cannot produce insulin (type 1 diabetes) or because the body does not make enough insulin or cannot use it effectively (type 2 diabetes).
Estonian: Diabeet (suhkurtõbi) on haigus, mille korral on vere glükoosisisaldus suur, sest organism ei tooda üldse insuliini (1. tüüpi diabeet) või ei teki organismis piisavalt insuliini või ei suuda organism seda efektiivselt kasutada (2. tüüpi diabeet).
English: The European Medicines Agency therefore decided that Fiasp's benefits outweigh the identified risks and it can be authorised for use in the EU.
Estonian: Seetõttu otsustas Euroopa Ravimiamet, et Fiaspi kasulikkus on suurem kui sellega kaasnevad riskid ja ravimi kasutamise võib ELis heaks kiita.
English: Fiasp (insulin aspart)
Estonian: Fiasp (aspartinsuliin)